HCA Healthcare reports Q3 2026 results this morning before the open, and the first instinct from the numbers is to frown. Analysts went in expecting earnings per share of about $6.65 on revenue of $19.33 billion. Those are already uninspiring expectations. The actual release, and the early-trading reaction, are landing into a comparison that was never going to look clean.
Here is what matters most: the comparison problem is largely manufactured. During the second quarter, HCA recognized approximately $400 million of incremental net benefit from Medicaid supplemental payment programs, driven largely by a newly approved Florida program. That one-time benefit sits in the base period HCA is now lapping. Any year-over-year margin analysis for Q3 needs to account for that before concluding the business has deteriorated. It has not deteriorated in the ways that actually matter for a hospital operator’s long-run value.
The Volume Picture Is What Counts
Admissions are the heartbeat of this business. Street models heading into this morning generally called for mid-single-digit revenue growth but only low-single-digit volume growth, with equivalent admissions up around the high-1% range. If those numbers hold, they confirm the operational recovery HCA started flagging at its Jefferies conference in September, where management reiterated a 2% to 3% equivalent-admissions growth framework and pointed out that occupancy remains in the low-to-mid 70s even with that volume. Volume growth did rebound in Q2, but the cleaner way to say it is that Q2 equivalent admissions rose 2.6% year-over-year.
The pressure is concentrated in elective surgeries, not emergent care. Management has framed the softer areas as tied to exchange disruption and related payer dynamics, plus some consumer deferral, which is better understood as a payer mix and affordability problem than a pure demand problem. People are still showing up at HCA hospitals.
Why Open Enrollment Adds Urgency Right Now
The broader policy context makes this quarter’s numbers matter beyond the single day’s move. ACA open enrollment for 2027 coverage begins November 1, and the picture for exchange enrollment is getting harder. Insurers have filed for a median proposed increase of about 15% for 2027, according to KFF’s review of filings from 276 insurers across all 50 states and the District of Columbia, one of the largest requested increases since 2018 and driven largely by underlying medical costs and a changing risk pool. The enhanced premium tax credits that had expanded ACA subsidies expired at the end of 2025, and the pre-ARP subsidy structure, including the 400% of Federal Poverty Level cutoff, is again in force for the 2027 plan year.
For HCA specifically, another enrollment contraction means more patients showing up uninsured. During Q2, the company said it experienced a payer mix shift driven by an increase in uninsured volume, primarily due to patients who lost coverage on the health insurance exchanges, and estimated this payer mix shift had an unfavorable impact on income before income taxes of approximately $400 million. A second consecutive enrollment season with large premium requests and a hard subsidy cliff suggests that headwind is not going away.
What Could Go Wrong
Guidance for the back half of 2026 has reflected a $1.0 billion to $1.2 billion negative impact from exchange dynamics, offset by $300 million to $500 million in net supplemental payment benefits. That is a wide range on the offset side. If Florida’s supplemental payments come in at the low end while exchange-driven uncompensated care tracks higher, margin pressure compounds through year-end. On valuation, HCA’s trailing P/E is in the mid-teens, which leaves less room for guidance disappointment without a reset.
The Bottom Line
HCA is not a broken business. The volume data is supportive, and management has been explicit about the exchange headwind. What today’s quarter actually tests is whether investors can distinguish a structural problem from a comparison problem. The roughly $400 million Florida Medicaid supplemental-payment benefit that boosted Q2 results was always going to make the next comparison look worse than it is. Strip that out, focus on admissions and occupancy, and HCA’s operational picture remains intact. The open enrollment season ahead is the real test: if 2027 exchange losses exceed the guidance band, the bear case gets real. Until that data arrives, the admissions trend earns the benefit of the doubt.